Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
30 participants
INTERVENTIONAL
2014-07-31
2019-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
OTHER
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
P943 PET Scan
[11C]-P943
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
[11C]-P943
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. voluntary, written, informed consent
3. physically healthy by medical history, physical, neurological, ECG, and laboratory examinations
4. for females, non-lactating, no longer of child-bearing potential (or agree to practice effective contraception during the study), and a negative serum pregnancy (B-HCG) test
5. English speaking
6. No other major Axis DSM-IV diagnosis present, besides required as below
1. DSM-IV criteria for Cocaine Abuse (305.60) or Cocaine Dependence (304.20)
2. recent street cocaine use
3. intravenous and/or smoked (crack/ freebase) use
4. positive urine toxicology screen for cocaine
1. No current, or history of, any DSM-IV diagnosis
2. No first-degree relative with history of psychotic, mood, or anxiety disorder
Exclusion Criteria
2. medical contraindications to MPH administration (e.g., history of cardiac problems, seizures, etc.)
3. drug or alcohol dependence (except nicotine)
4. a primary major DSM-IV psychiatric diagnosis (schizophrenia, bipolar disorder, etc.), unrelated to cocaine or pathological gambling
5. positive answers on the cardiac screening questionnaire that may place the subject at higher risk, as determined by cardiologist review of both the questionnaire responses and screening ECG
6. current use of psychotropic and/or potentially psychoactive prescription medication
7. physical or laboratory (B-HCG) evidence of pregnancy
8. clotting disorders or recent anticoagulant therapy
9. MRI-incompatible implants and other contraindications for MRI (i.e., aneurysm clip, metal fragments, internal electrical devices such as a cochlear implant, spinal cord stimulator or pacemaker)
10. history of claustrophobia or feeling of inability to lie still on his back for the PET or MRI scans
11. history of prior radiation exposure for research purposes within the past year such that participation in this study would place them over Radioactive Drug Research Committee (RDRC) limits for annual radiation exposure. This guideline is an effective dose of 5 rem received per year
12. donation or loss of 550 mL of blood or more (including plasmapheresis) or receipt of a transfusion of any blood product within 8 weeks prior to the first dose of study drug
13. use any prescription medications and/or over-the-counter medications, vitamins and/or herbal supplements within 2 weeks prior to study and for the duration of the study without approval from the study doctor
14. eat grapefruit or grapefruit products, and drink alcohol, and anything containing caffeine 3 days before study and during study
15. For CD subjects, \< 1 year of cocaine dependence
16. Subjects with current, past, or anticipated exposure to radiation in the workplace
18 Years
50 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Yale University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Marc Potenza, PhD, MD
Role: PRINCIPAL_INVESTIGATOR
Yale University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Connecticut Mental Health Center
New Haven, Connecticut, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
0811004457
Identifier Type: -
Identifier Source: org_study_id